RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising lymphoma combo trial halted over safety issues
Disease control OngoingThis study tested a new drug combination (tolinapant plus decitabine/cedazuridine) in 33 adults with a rare, hard-to-treat blood cancer called peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find a safe dose and see if the combina…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for Tough-to-Treat lymphoma: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called valemetostat in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 155 adults will tak…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC